Dianthus Therapeutics, Inc. (DNTH)

Market Cap	1.44B
Revenue (ttm)	4.85M
Net Income (ttm)	-114.75M
Shares Out	38.68M
EPS (ttm)	-3.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	883,504
Open	37.17
Previous Close	37.16
Day's Range	36.23 - 37.94
52-Week Range	13.37 - 38.59
Beta	1.00
Analysts	Strong Buy
Price Target	61.57 (+64.93%)
Earnings Date	Nov 6, 2025

About DNTH

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company’s lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 78
• Stock Exchange: NASDAQ
• Ticker Symbol: DNTH
• Website: https://dianthustx.com

Financial Performance

In 2024, Dianthus Therapeutics's revenue was $6.24 million, an increase of 120.63% compared to the previous year's $2.83 million. Losses were -$84.97 million, 95.1% more than in 2023.

Analyst Summary

According to 9 analysts, the average rating for DNTH stock is "Strong Buy." The 12-month stock price target is $61.57, which is an increase of 64.93% from the latest price.

Price Target

$61.57

(64.93% upside)

Analyst Consensus: Strong Buy